Sutro Biopharma Q3 2026 Results: Net Loss of $31.5M, Loss Narrows
Sutro Biopharma reported a net loss of $108.5 million for the nine months ended September 30, 2026, compared to a $144.3 million loss in the prior year period. Total revenue decreased significantly to $33.5 million from $90.8 million year-over-year, while operating expenses were reduced through restructuring and lower research and development spending.
- Key figure
- Net loss $31.5M